Table 4. Patients who were treated with pembrolizumab beyond disease progression.
| Study case No. | Age, years | Gender (M/F) | Histology | PD-L1 TPS | Best response on pembrolizumab | Sites of disease progression on pembrolizumab | Type of local ablative treatment | PPS (months) | PPS rates at 6 and 12 months |
|---|---|---|---|---|---|---|---|---|---|
| 01& | 62 | M | Sarcomatoid carcinoma | 75% | PR | Brain (new) | WBRT | 6.9 | 88.9% and 71.1% |
| 02& | 48 | M | Squamous | 60% | PR | Single lymph-nodal station | Lymph-nodal RT | 7.4+ | |
| 03& | 72 | M | Squamous | 100% | PR | Single lung lesion | Lung stereotactic RT | 14.7+ | |
| 04& | 62 | F | Adenoca. | 80% | PR | Single renal lesion | Renal RT | 24.6+ | |
| 05& | 78 | F | Squamous | 70% | PR | Single lung and lymph-nodal station | Lung and lymph-nodal stereotactic RT | 4.6+ | |
| 06& | 69 | F | NSCLC NOS | 70% | SD | Brain (new) | WBRT | 7.1+ | |
| 07& | 87 | M | Adenoca. | 60% | PR | Single lung lesion | Lung RT | 4.2+ | |
| 08& | 60 | M | Adenoca. | 70% | PR | Brain (pre-existing) | WBRT | 4.0+ | |
| 09& | 51 | M | Adenoca. | 60% | PD | Brain (new) | WBRT | 4.6+ | |
| 10# | 69 | F | Adenoca. | 60% | PD | Pericardial effusion* | – | 2.1 | 63.3% and 0% |
| 11# | 64 | F | Adenoca. | 80% | PR | Pericardial effusion* | – | 6.9+ | |
| 12# | 79 | M | Adenoca. | 75% | SD | Lung and pleura | – | 3.5 | |
| 13# | 72 | M | NSCLC NOS | 95% | PR | Lung | – | 7.1+ | |
| 14 | 58 | F | Squamous | 80% | PD | Lung, liver, and bones** | – | 1.2 | |
| 15 | 71 | M | Squamous | 95% | PD | Lung, pleura, and soft tissues | – | 5.8 | |
| 16 | 72 | M | Squamous | 90% | SD | Multiple lymph-nodal stations | – | 8.0 | |
| 17 | 74 | M | Sarcomatoid carcinoma | 60% | PR | Multiple lung lesions | – | 5.9+ | |
| 18 | 72 | F | Adenoca. | 60% | SD | Lung, liver, and extra-thoracic lymph-nodal stations | – | 3.4+ |
&, patients with progressive disease at ≤2 organ sites treated with local ablative radiotherapy; #, patients with progressive disease at ≤2 organ sites; *, treated by pericardial drainage only; **, palliative bone radiotherapy administered; +, sign indicates alive patients at the time of the last contact. Adenoca., adenocarcinoma; No., number; NSCLC, non-small cell lung cancer; NOS, not otherwise specified; PD, progressive disease; PR, partial response; PPS, post-progression survival; RT, radiotherapy; SD, stable disease; TPS, tumor proportion score; WBRT, whole brain radiotherapy.